The National Academies of Sciences, Engineering, and Medicine (NASEM) released proceedings from a workshop, dubbed Exploring the Frontiers of Innovation to Tackle Microbial Threats, help in December 2019. The workshop occurred, fittingly, in the same month as the birth of SARS-CoV-2, the viral agent of the COVID-19 pandemic the world is currently besieged by. This 1.5-day workshop of the Forum on Microbial Threats examined key developments in scientific, technological, and social innovations against microbial threats: diagnostics, vaccine development, antimicrobial therapies, nonpharmaceutical interventions, and disease surveillance tools. The proceedings outline important lessons learned, particularly regarding spurred innovations, from the poliovirus eradication campaign as well as the the on-the-ground work to quell Ebola virus disease outbreaks in West Africa and the Democratic Republic of the Congo. Dr. Rick Bright, the former director of the Biomedical Advanced Research and Development Authority (BARDA), moderated the panel on incubating R&D through novel ecosystems. The output also includes content from panels regarding systematic approaches to motivate innovations in antimicrobial resistance R&D, barriers to access and use of innovations, and strategies to overcome barriers to innovation uptake. The full report can be found here.
The Federation of American Scientists (FAS) announced the launch of its COVID-19 Rapid Response Task Force, an amalgamation of dozens of scientists and experts from across the United States. The Task Force is being established as a resource for federal and state legislators as well as other policymakers seeking sound scientific information regarding COVID-19 related topics. Such topics span biomedical research needs, diagnostic test development, and contact tracing challenges, all of which are important to reopening while containing the virus. The Task Force provides an open channel of communication to experts in numerous areas of need.
Student Spotlight: Laura Schmidt Denlinger
Schar School Biodefense PhD student Laura Schmidt Denlinger was promoted to the role of Deputy Team Chief for Counterproliferation Programs in the State Department Bureau of International Security and Nonproliferation‘s Office of Cooperative Threat Reduction (ISN/CTR). As such, she coordinates CTR capacity-building programs that strengthen foreign partners’ ability to implement United Nations Security Council Resolutions regarding WMD proliferation by North Korea and Iran, as well as the Chemical Security Program, Partnership for Nuclear Threat Reduction Program, and other lines of effort to counter emerging WMD proliferation threats.
GHSA Chair COVID-19 Statement
Dr. Roland Driece, Chair of the Global Health Security Agenda, recently provided a statement on the ongoing COVID-19 pandemic and the role of the GHSA2024. Emphasizing the role of international coordination and unification of efforts from governments to NGOs, Driece noted that this event should not be seen as an indicator that our efforts to prepare have failed, but rather that “Because of the work of GHSA, we have more information than in any previous outbreak about which countries have the most prepared systems, and where the international community needs to direct assistance. As countries and partners work to respond to spread of COVID-19, national plans supported by the International Health Regulations and Joint External Evaluations are guiding action and providing resources for decision making, prioritisation, and actions.” Through the extraordinary efforts of everyone ranging from lab to information systems, this naturally occurring event coordinated to respond and it will require the continued investment in preparedness to response and prevent future pandemics.
New Evidence on Disease Dynamics
The raging pandemic has spurred a deluge of interesting new and early release articles in Emerging Infectious Diseases, a journal published by the Centers for Disease Control and Prevention (CDC). A study transmission examining a cluster of COVID-19 cases associated with a shopping mall in Wenzhou, China indicated indirect transmission of the causative agent, likely via contaminated objects, virus aerosolization in confined spaces, or spread from close contact with asymptomatic infected persons. Another research team collected information on individual case reports and domestic travel across China to estimate important epidemiological measures, such as the disease’s incubation period and R0. Specifically, they found that in the early days of the outbreak, the doubling time was 2.3-3.3 days and the median R0 could hit 5.7, numbers that support the criticality of surveillance, contact tracing, and social distancing to slow transmission. A third study confirmed asymptomatic and human-to-human transmission via close contacts in family and hospital settings, information useful for practice in clinical diagnosis and treatment. Relatedly, further research found evidence supporting the transmission of SARS-CoV-2 while an infected patient was presymptomatic or asymptomatic. Transmission of the virus from presymptomatic and asymptomatic cases impacts the types of public health interventions needed to contain the virus. An analysis of coronavirus patients from Vietnam indicated that the virus was transmitted from a traveler from China. Additionally, an asymptomatic patient showed viral shedding, more evidence that transmission can occur in the absence of clinical signs and symptoms. An article examining transmission from a presymptomatic attendee at a meeting in Germany found evidence that the disease was further transmitted via handshaking and face-to-face contact. Read all these articles here.